A citation-based method for searching scientific literature

Meina Wang, Roy S Herbst, Chris Boshoff. Nat Med 2021
Times Cited: 2







List of co-cited articles
2 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Tony S K Mok, Yi-Long Wu, Iveta Kudaba, Dariusz M Kowalski, Byoung Chul Cho, Hande Z Turna, Gilberto Castro, Vichien Srimuninnimit, Konstantin K Laktionov, Igor Bondarenko,[...]. Lancet 2019
100

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Achim Rittmeyer, Fabrice Barlesi, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish M Gadgeel, Toyoaki Hida, Dariusz M Kowalski, Manuel Cobo Dols,[...]. Lancet 2017
100



Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer.
Scott Gettinger, Jungmin Choi, Katherine Hastings, Anna Truini, Ila Datar, Ryan Sowell, Anna Wurtz, Weilai Dong, Guoping Cai, Mary Ann Melnick,[...]. Cancer Discov 2017
260
50

Failure of Immunotherapy-The Molecular and Immunological Origin of Immunotherapy Resistance in Lung Cancer.
Justyna Błach, Kamila Wojas-Krawczyk, Marcin Nicoś, Paweł Krawczyk. Int J Mol Sci 2021
1
100

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
50

Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11).
Yunpeng Yang, Zhehai Wang, Jian Fang, Qitao Yu, Baohui Han, Shundong Cang, Gongyan Chen, Xiaodong Mei, Zhixiong Yang, Rui Ma,[...]. J Thorac Oncol 2020
50
50

Chimeric antigen receptor T cells for sustained remissions in leukemia.
Shannon L Maude, Noelle Frey, Pamela A Shaw, Richard Aplenc, David M Barrett, Nancy J Bunin, Anne Chew, Vanessa E Gonzalez, Zhaohui Zheng, Simon F Lacey,[...]. N Engl J Med 2014
50

TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
Joe-Marc Chauvin, Ornella Pagliano, Julien Fourcade, Zhaojun Sun, Hong Wang, Cindy Sander, John M Kirkwood, Tseng-hui Timothy Chen, Mark Maurer, Alan J Korman,[...]. J Clin Invest 2015
368
50

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
Robert J Motzer, Bernard Escudier, David F McDermott, Saby George, Hans J Hammers, Sandhya Srinivas, Scott S Tykodi, Jeffrey A Sosman, Giuseppe Procopio, Elizabeth R Plimack,[...]. N Engl J Med 2015
50

PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee.
Sylvie Lantuejoul, Ming Sound-Tsao, Wendy A Cooper, Nicolas Girard, Fred R Hirsch, Anja C Roden, Fernando Lopez-Rios, Deepali Jain, Teh-Ying Chou, Noriko Motoi,[...]. J Thorac Oncol 2020
86
50

Comprehensive Analysis of Hypermutation in Human Cancer.
Brittany B Campbell, Nicholas Light, David Fabrizio, Matthew Zatzman, Fabio Fuligni, Richard de Borja, Scott Davidson, Melissa Edwards, Julia A Elvin, Karl P Hodel,[...]. Cell 2017
347
50

Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study).
Giuseppe Giaccone, Channa Debruyne, Enriqueta Felip, Paul B Chapman, Stefan C Grant, Michael Millward, Luc Thiberville, Giannicola D'addario, Corneel Coens, Lisa S Rome,[...]. J Clin Oncol 2005
150
50

Reprogramming the tumor microenvironment to enhance adoptive cellular therapy.
Paul A Beavis, Clare Y Slaney, Michael H Kershaw, David Gyorki, Paul J Neeson, Phillip K Darcy. Semin Immunol 2016
35
50

Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma.
Suzanne George, Diana Miao, George D Demetri, Dennis Adeegbe, Scott J Rodig, Sachet Shukla, Mikel Lipschitz, Ali Amin-Mansour, Chandrajit P Raut, Scott L Carter,[...]. Immunity 2017
237
50

High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability.
R Dolcetti, A Viel, C Doglioni, A Russo, M Guidoboni, E Capozzi, N Vecchiato, E Macrì, M Fornasarig, M Boiocchi. Am J Pathol 1999
321
50

Soluble Biomarkers with Prognostic and Predictive Value in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy.
Beatriz Honrubia-Peris, Javier Garde-Noguera, Jose García-Sánchez, Nuria Piera-Molons, Antonio Llombart-Cussac, María Leonor Fernández-Murga. Cancers (Basel) 2021
1
100

Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.
Triparna Sen, B Leticia Rodriguez, Limo Chen, Carminia M Della Corte, Naoto Morikawa, Junya Fujimoto, Sandra Cristea, Thuyen Nguyen, Lixia Diao, Lerong Li,[...]. Cancer Discov 2019
231
50

TIGIT: A Key Inhibitor of the Cancer Immunity Cycle.
Nicholas A Manieri, Eugene Y Chiang, Jane L Grogan. Trends Immunol 2017
148
50

Immunotherapy as a strategy for the treatment of non-small-cell lung cancer.
Gregory E Holt, Eckhard R Podack, Luis E Raez. Therapy 2011
37
50

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.
Tina Cascone, William N William, Annikka Weissferdt, Cheuk H Leung, Heather Y Lin, Apar Pataer, Myrna C B Godoy, Brett W Carter, Lorenzo Federico, Alexandre Reuben,[...]. Nat Med 2021
40
50

Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.
Roy S Herbst, Giuseppe Giaccone, Filippo de Marinis, Niels Reinmuth, Alain Vergnenegre, Carlos H Barrios, Masahiro Morise, Enriqueta Felip, Zoran Andric, Sarayut Geater,[...]. N Engl J Med 2020
188
50

A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer.
G Giaccone, L A Bazhenova, J Nemunaitis, M Tan, E Juhász, R Ramlau, M M van den Heuvel, R Lal, G H Kloecker, K D Eaton,[...]. Eur J Cancer 2015
124
50

PD-1 blockade induces responses by inhibiting adaptive immune resistance.
Paul C Tumeh, Christina L Harview, Jennifer H Yearley, I Peter Shintaku, Emma J M Taylor, Lidia Robert, Bartosz Chmielowski, Marko Spasic, Gina Henry, Voicu Ciobanu,[...]. Nature 2014
50


Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
Roy S Herbst, Jean-Charles Soria, Marcin Kowanetz, Gregg D Fine, Omid Hamid, Michael S Gordon, Jeffery A Sosman, David F McDermott, John D Powderly, Scott N Gettinger,[...]. Nature 2014
50

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Julie Brahmer, Karen L Reckamp, Paul Baas, Lucio Crinò, Wilfried E E Eberhardt, Elena Poddubskaya, Scott Antonia, Adam Pluzanski, Everett E Vokes, Esther Holgado,[...]. N Engl J Med 2015
50

Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial).
S Ramalingam, J Crawford, A Chang, C Manegold, R Perez-Soler, J-Y Douillard, N Thatcher, F Barlesi, T Owonikoko, Y Wang,[...]. Ann Oncol 2013
37
50

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Roy S Herbst, Paul Baas, Dong-Wan Kim, Enriqueta Felip, José L Pérez-Gracia, Ji-Youn Han, Julian Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung-Ju Ahn,[...]. Lancet 2016
50

Randomized controlled phase III trial of adjuvant chemo-immunotherapy with activated killer T cells and dendritic cells in patients with resected primary lung cancer.
Hideki Kimura, Yukiko Matsui, Aki Ishikawa, Takahiro Nakajima, Mitsuru Yoshino, Yuichi Sakairi. Cancer Immunol Immunother 2015
50
50

Acquired and intrinsic resistance in cancer immunotherapy.
Sander Kelderman, Ton N M Schumacher, John B A G Haanen. Mol Oncol 2014
109
50

Immunotherapy for lung cancer.
Antonius Steven, Scott A Fisher, Bruce W Robinson. Respirology 2016
91
50

Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133).
Stephen V Liu, Martin Reck, Aaron S Mansfield, Tony Mok, Arnaud Scherpereel, Niels Reinmuth, Marina Chiara Garassino, Javier De Castro Carpeno, Raffaele Califano, Makoto Nishio,[...]. J Clin Oncol 2021
30
50

Second-line treatment of non small cell lung cancer by biweekly gemcitabine and docetaxel +/- granulocyte-macrophage colony stimulating factor and low dose aldesleukine.
Pierpaolo Correale, Salvatora Tindara Miano, Cinzia Remondo, Cristina Migali, Maria Saveria Rotundo, Paolo Macrì, Pierosandro Tagliaferri, Michele Caraglia, Giuseppe Gotti, Guido Francini. Cancer Biol Ther 2009
17
50

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
Leena Gandhi, Delvys Rodríguez-Abreu, Shirish Gadgeel, Emilio Esteban, Enriqueta Felip, Flávia De Angelis, Manuel Domine, Philip Clingan, Maximilian J Hochmair, Steven F Powell,[...]. N Engl J Med 2018
50

Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma.
Tomonari Kinoshita, Chie Kudo-Saito, Reiko Muramatsu, Tomonobu Fujita, Miyuki Saito, Haruna Nagumo, Toshiharu Sakurai, Shinobu Noji, Emi Takahata, Tomonori Yaguchi,[...]. Eur J Cancer 2017
42
50


Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial.
Robert Jotte, Federico Cappuzzo, Ihor Vynnychenko, Daniil Stroyakovskiy, Delvys Rodríguez-Abreu, Maen Hussein, Ross Soo, Henry J Conter, Toshiyuki Kozuki, Kuan-Chieh Huang,[...]. J Thorac Oncol 2020
108
50

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
Stephen M Ansell, Alexander M Lesokhin, Ivan Borrello, Ahmad Halwani, Emma C Scott, Martin Gutierrez, Stephen J Schuster, Michael M Millenson, Deepika Cattry, Gordon J Freeman,[...]. N Engl J Med 2015
50

Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.
Luis Paz-Ares, Alexander Luft, David Vicente, Ali Tafreshi, Mahmut Gümüş, Julien Mazières, Barbara Hermes, Filiz Çay Şenler, Tibor Csőszi, Andrea Fülöp,[...]. N Engl J Med 2018
50

STAT3 in CD8+ T Cells Inhibits Their Tumor Accumulation by Downregulating CXCR3/CXCL10 Axis.
Chanyu Yue, Shudan Shen, Jiehui Deng, Saul J Priceman, Wenzhao Li, Austin Huang, Hua Yu. Cancer Immunol Res 2015
50
50


Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.
Jeffrey Weber, Mario Mandala, Michele Del Vecchio, Helen J Gogas, Ana M Arance, C Lance Cowey, Stéphane Dalle, Michael Schenker, Vanna Chiarion-Sileni, Ivan Marquez-Rodas,[...]. N Engl J Med 2017
50

Chemotherapy with or without low-dose interleukin-2 in advanced non-small cell lung cancer: results from a phase III randomized multicentric trial.
Laura Ridolfi, Oscar Bertetto, Antonio Santo, Emanuele Naglieri, Massimo Lopez, Francesco Recchia, Paolo Lissoni, Marco Galliano, Franco Testore, Camillo Porta,[...]. Int J Oncol 2011
27
50

A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers.
S N Gettinger, J Choi, N Mani, M F Sanmamed, I Datar, Ryan Sowell, Victor Y Du, E Kaftan, S Goldberg, W Dong,[...]. Nat Commun 2018
75
50

Genomic approaches to lung cancer.
Roman K Thomas, Barbara Weir, Matthew Meyerson. Clin Cancer Res 2006
32
50

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab.
David R Gandara, Sarah M Paul, Marcin Kowanetz, Erica Schleifman, Wei Zou, Yan Li, Achim Rittmeyer, Louis Fehrenbacher, Geoff Otto, Christine Malboeuf,[...]. Nat Med 2018
507
50

Immune checkpoint inhibitors in advanced non-small cell lung cancer.
Hazem I Assi, Alice O Kamphorst, Nour M Moukalled, Suresh S Ramalingam. Cancer 2018
59
50

Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, David F McDermott, Robert W Weber, Jeffrey A Sosman, John B Haanen, Rene Gonzalez, Caroline Robert, Dirk Schadendorf, Jessica C Hassel,[...]. N Engl J Med 2010
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.